Samsara Therapeutics Inc.
Lewes, US · Founded 2018 · Delaware corporation · 1 known investors
Biopharmaceutical company developing first-in-class therapeutics for rare genetic and neurodegenerative diseases with a focus on autophagy enhancement.
Biotech
Founders & leadership
JE
Jens EcksteinNamed on SEC filing
Investors · 1
Reported raises · per SEC filings
Form D private placements$10.3M disclosed across 1 round · 2021
▶$10.3MraisedJul 2021 · 17 investors · BiotechnologyRule 506(b)
▶$10.3MraisedJul 2021 · 17 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jens EcksteinExecutive Officer, Director
- Offering amount
- $12.7M
- Amount sold
- $10.3M
- First sale
- Jul 2021
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Samsara Therapeutics Inc. do?
- Biopharmaceutical company developing first-in-class therapeutics for rare genetic and neurodegenerative diseases with a focus on autophagy enhancement.
- Who are Samsara Therapeutics Inc.'s investors?
- Samsara Therapeutics Inc.'s investors include Korify Capital.
- How much funding has Samsara Therapeutics Inc. raised?
- Samsara Therapeutics Inc. has disclosed $10.3M raised across 1 round.
- Where is Samsara Therapeutics Inc. headquartered?
- Samsara Therapeutics Inc. is headquartered in Lewes, US.